GIP + atropine

GIP + atropine is a hypothetical or investigational combination of two agents: a glucose-dependent insulinotropic polypeptide (GIP) pathway modulator and atropine, an antimuscarinic agent. GIP is an incretin hormone that stimulates insulin secretion in response to oral glucose, acting via the GIP receptor on pancreatic beta cells. Atropine is a competitive antagonist of muscarinic acetylcholine receptors, used clinically for its anticholinergic effects such as reducing secretions and inhibiting vagal activity. While there are established pharmaceutical combinations of atropine with other drugs (e.g., diphenoxylate or difenoxin) for diarrhea management[1][2][4][7], there are no approved or widely recognized products combining GIP-targeted therapy with atropine as active ingredients. However, research has explored the interaction between incretin hormones (such as GLP-1 and potentially GIP) and cholinergic signaling; muscarinic blockade by atropine can modulate the metabolic effects of incretins[6][10]. No marketed product or clinical trial currently exists specifically for "GIP + atropine" as a fixed combination.